Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

561.49
-1.6700-0.30%
Post-market: 562.060.5700+0.10%18:28 EDT
Volume:745.65K
Turnover:418.61M
Market Cap:60.09B
PE:14.65
High:570.35
Open:556.04
Low:552.97
Close:563.16
Loading ...

Regeneron assumed at Overweight from Neutral at Cantor Fitzgerald

TIPRANKS
·
2 hours ago

Regeneron Announces Investor Conference Presentations

GlobeNewswire
·
2 hours ago

Wolfe Research Adjusts Regeneron Pharmaceuticals PT to $950 From $1,000, Keeps Outperform Rating

MT Newswires Live
·
Yesterday

BUZZ - Nasdaq top and bottom performing stocks at about 11:01 a.m. EDT on 2025-04-21

Reuters
·
Yesterday

Regeneron's FDA Setback on Eylea HD Dosing 'No Biggie,' Says Oppenheimer

MT Newswires Live
·
Yesterday

Regeneron CRL for Eylea extension not surprising, says Oppenheimer

TIPRANKS
·
Yesterday

Regeneron receives complete response letter for Eylea extended dosing

TIPRANKS
·
Yesterday

Sanofi & Regeneron's Dupixent Receives FDA Nod for Urticaria

Zacks
·
Yesterday

Sector Update: Health Care

MT Newswires Live
·
Yesterday

Analysts Offer Insights on Healthcare Companies: Regeneron (REGN) and Surgery Partners (SGRY)

TIPRANKS
·
Yesterday

FDA Approves Dupixent for Chronic Hives in Patients Unresponsive to Antihistamines

MT Newswires Live
·
Yesterday

Regeneron Pharmaceuticals Says FDA Rejects Bid for Extended Eye Drug Dosing Intervals

MT Newswires Live
·
Yesterday

Regeneron announces FDA accepted Priority Review sBLA for EYLEA HD

TipRanks
·
19 Apr

Regeneron to Reassess Strategy for Retinal Condition Treatment After FDA Rejects Dosing Plan

Dow Jones
·
19 Apr

Regeneron Provides Update on Eylea Hd® (Aflibercept) Injection 8 Mg Supplemental Biologics License Application

THOMSON REUTERS
·
19 Apr

Regeneron Pharmaceuticals Inc - Crl Does Not Identify Safety or Efficacy Issues With Eylea Hd

THOMSON REUTERS
·
19 Apr

Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application

GlobeNewswire
·
19 Apr

BRIEF-Dupixent Approved In US As First New Targeted Therapy In Over Decade For Chronic Spontaneous Urticaria

Reuters
·
19 Apr

Regeneron, Sanofi Get FDA Approval For Dupixent in Skin Disease CSU

Dow Jones
·
18 Apr

Sanofi-Regeneron's Dupixent gets FDA's nod for skin condition

Reuters
·
18 Apr